DOCMORRIS : Warburg Research reiterates its Neutral rating

Published on 05/12/2025 at 05:43

MarketScreener with dpa-AFX Analyser

Warburg Research's research confirms his advice and maintains his neutral opinion on the stock. Previously set at CHF 19, the target price is lowered to CHF 10.80.

Latest news about DocMorris AG

Swiss Stocks Close Lower; Doc Morris Shares Up	Jul. 15	MT
DOCMORRIS : Deutsche Bank reiterates its Neutral rating	Jul. 15	ZD
DocMorris Wins Extension for CardLink Product Use in Germany	Jul. 15	MT
DocMorris AG - Gematik extends Cardlink approval until January 2027	Jul. 15	RE
DOCMORRIS : Receives a Buy rating from Jefferies	Jul. 11	ZD
DOCMORRIS : Deutsche Bank reaffirms its Neutral rating	Jul. 03	ZD
Court Ruling: High-Value Vouchers for E-Prescriptions Deemed Unlawful	Jul. 02	DP
North Rhine-Westphalian Health Minister wants to strengthen pharmacies	Jun. 09	DP
DOCMORRIS : Jefferies reiterates its Buy rating	Jun. 04	ZD
DOCMORRIS : Upgraded from Sell to Buy by Baader Bank	Jun. 03	ZD
DOCMORRIS : Hauck & Aufhauser reiterates its Buy rating	May. 27	ZD
DOCMORRIS : Jefferies keeps its Buy rating	May. 26	ZD
Swiss stocks - Factors to watch on May 22	May. 22	RE
DocMorris Expects CHF200 Million from Rights Offering	May. 22	MT
Docmorris Announces Number Of Shares Sold In Rights Offering	May. 21	RE
Swiss Equities Close Higher; DocMorris Shares Jump	May. 20	MT
Pelion Takes Minority Stake in DocMorris	May. 20	MT
Docmorris Was Informed By Pelion That It Has Acquired A Stake Of 9.68% In Docmorris	May. 20	RE
DocMorris AG announced that it expects to receive funding from Pelion S.A.	May. 19	CI
DOCMORRIS : Warburg Research reiterates its Neutral rating	May. 12	ZD
DocMorris Shareholders Approve Capital Increase Proposal	May. 08	MT
DOCMORRIS : Sell rating from Baader Bank	May. 08	ZD
DocMorris AG Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 07	CI
Redcare Pharmacy back in profit as expected – share price down	May. 06	DP
Redcare Pharmacy wants to grow without acquisitions	Apr. 24	DP